<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005069</url>
  </required_header>
  <id_info>
    <org_study_id>DLBS-32-0309</org_study_id>
    <nct_id>NCT01005069</nct_id>
  </id_info>
  <brief_title>Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus</brief_title>
  <official_title>Phase-II Clinical Study: A Randomized, Double Blind, Dose Ranging, and Controlled Study to Evaluate the Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dexa Medica Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dexa Medica Group</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate clinical efficacy and safety of DLBS 32 in the
      management of subjects with type-II-diabetes mellitus and to determine the minimal effective
      dose of DLBS 32 for subjects with type-II-diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of venous Fasting Plasma Glucose from baseline</measure>
    <time_frame>every 2-week interval over 6 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of 2h-post-prandial plasma glucose from baseline</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of homeostasis model assessment of insulin resistance (HOMA-IR) from baseline</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of high sensitivity C-reactive protein (hs-CRP) from baseline</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Function, Renal Function, Adverse events</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid profile from baseline</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Treatment I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DLBS-32</intervention_name>
    <description>DLBS-32 50 mg once daily and lifestyle modification</description>
    <arm_group_label>Treatment I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DLBS-32</intervention_name>
    <description>DLBS-32 100 mg once daily and lifestyle modification</description>
    <arm_group_label>Treatment II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DLBS-32</intervention_name>
    <description>DLBS-32 200 mg once daily and lifestyle modification</description>
    <arm_group_label>Treatment III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DLBS-32</intervention_name>
    <description>DLBS-32 300 mg once daily and lifestyle modification</description>
    <arm_group_label>Treatment IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Placebo capsules once daily and lifestyle modification</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fasting capillary blood glucose of 127-249 mg/dL at screening

          -  BMI &gt;= 18.5 kg/m^2 or waist circumference of &gt;= 90 cm (male) or &gt;= 80 cm (female)

          -  Normal liver function

          -  Normal renal function

          -  OHA-naive type-II-diabetic patients

        Exclusion Criteria:

          -  Symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia

          -  Uncontrolled hypertension

          -  History of or current treatment with insulin

          -  Current treatment with systemic corticosteroids or herbal (alternative) medicines

          -  History of renal and/or liver disease

          -  Pregnant or breast feeding females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ketut Suastika, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Endocrinology and Metabolic Disease University of Udayana / Sanglah Denpasar Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nuniek E Nugrahini, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of internal medicine, RSUD Tarakan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanglah Hospital Denpasar</name>
      <address>
        <city>Denpasar</city>
        <state>Bali</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RSUD Tarakan</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2009</study_first_submitted>
  <study_first_submitted_qc>October 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2009</study_first_posted>
  <last_update_submitted>September 26, 2010</last_update_submitted>
  <last_update_submitted_qc>September 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2010</last_update_posted>
  <keyword>diabetes mellitus</keyword>
  <keyword>DLBS-32</keyword>
  <keyword>fasting plasma glucose</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

